Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.69 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.53 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069040 | 1.00 | FAAH (0.79) | FAAHFFAR1FFAR4TRPV1P2RY10 | |
| SCHEMBL14253318 | 0.94 | FAAH (0.74) | FAAHFFAR1FFAR4TRPV1P2RY10 | |
| SCHEMBL11731589 | 0.92 | FAAH (0.76) | FAAHFFAR1FFAR4TRPV1EPHX2 | |
| SCHEMBL15006956 | 0.91 | FAAH (0.81) | FAAHFFAR1FFAR4TRPV1EPHX2 | |
| SCHEMBL395759 | 0.91 | FAAH (0.81) | FAAHFFAR1FFAR4TRPV1EPHX2 | |
| SCHEMBL11778109 | 0.91 | FAAH (0.81) | FAAHFFAR1FFAR4TRPV1EPHX2 | |
| SCHEMBL5944382 | 0.90 | FAAH (0.63) | FAAHTRPV1P2RY10GPR174EPHX2 | |
| SCHEMBL5406277 | 0.90 | FAAH (0.63) | FAAHTRPV1P2RY10GPR174EPHX2 | |
| SCHEMBL15007012 | 0.90 | FAAH (0.79) | FAAHFFAR1FFAR4TRPV1EPHX2 | |
| SCHEMBL29634690 | 0.90 | FAAH (0.79) | FAAHFFAR1FFAR4TRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6600059-B2 | Protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents. Even more particularly, the present invention provides compositions and methods for treating or prophylactically inhibiting | VIRGINIA COMMONWEALTH UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| US-20030078417-A1 | Cytoprotective compounds | FRANSON RICHARD C (US) | 2003-04-24 | — | — | US | disclosed |
| US-6423855-B2 | PREVENTION LYSIS; OXIDATION RESISTANCE | VIRGINIA COMMONWEALTH UNIVERSITY | 2002-07-23 | — | — | US | disclosed |
| US-20020002296-A1 | Cytoprotective Compounds | FRANSON RICHARD C (US) | 2002-01-03 | — | — | US | disclosed |
| US-6020510-A | Cytoprotective compounds | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5859271-A | Cytoprotective compounds | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078417-A1 | Cytoprotective compounds | PLA2G4B, PLA2G4C, GPX4 | FAAH 317/4885FFAR1 1259/4885FFAR4 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.